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The management of androgen independent prostate cancer is increasingly disputed. Diethylstilbestrol and steroids have useful
second-line activity in its management. The value of chemotherapy still remains contentious. This paper reports a phase 2 study of
two orally active chemotherapy drugs in patients who are absolutely hormone refractory having failed primary androgen blockade
and combined oestrogens and corticosteroids. In total, 37 patients who were biochemically castrate with absolute hormone
refractory prostate cancer and performance status of 0–3 were enrolled. Therapy consisted of chlorambucil 1mgkg
 1 given as 6mg
a day until the total dose was reached and lomustine 2mgkg
 1 given every 56 days (CL56). During this time all hormone therapy was
stopped. One patient normalised his PSA with a further two having a greater than 50% decline leading to an objective response rate
of 10%. The median time to progression was 3.6 months with an overall survival of 7.1 months. The median survival of this group of
patients from first becoming androgen independent was 23.5 months. Eight of 17 (47%) patients who were subsequently re-
challenged with hormonal therapy following failure of chemotherapy had a further PSA reduction, three (17%) of which were 450%.
The median progression-free interval for the eight patients was 4 months. In conclusion, CL56 has a low objective response rate in
the management of absolute hormone refractory prostate cancer. Toxicity was mild. Re-induction of hormone sensitivity following
failure of chemotherapy was an unexpected finding that requires further study.
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The majority of patients with locally advanced or metastatic
prostate cancer treated by continuous androgen deprivation using
either maximum androgen blockade (MAB) or GnRH analogue
with deferred antiandrogens and then antiandrogen withdrawal
ultimately become hormone resistant after 1–2 years treatment.
Once hormone resistant their median survival then falls to about 1
year (Tannock et al, 1996).
Following the publication of three phase III studies comparing
mitoxantrone and prednisone to prednisone alone in androgen
independent prostate cancer, which demonstrated an improve-
ment in symptom control despite failure to improve survival,
chemotherapy has become accepted as having a role at this point
in the disease (Tannock et al, 1996). More recently, the
presentation of two large randomised phase III trials comparing
mitoxantrone and docetaxel showed a significant survival advan-
tage in favour of docetaxel (Eisenberger et al, 2004; Petrylak et al,
2004).
Oestrogens such as fosfosterol (Orlando et al, 2000) and
diethylstilbestrol may produce responses in androgen independent
patients. In one study the combination of low-dose diethystilboes-
trol and hydrocortisone produced a PSA response in 76%
(Farrugia et al, 2000). Preliminary data suggesting that the
response was more durable with dexamethasone than cortisone
(Bhattacharyya et al, 2003) has led to that combination becoming
the standard of care in our unit with chemotherapy only being
used after second-line endocrine treatment fails.
In an attempt to investigate the true response rate in patients
who had failed primary androgen deprivation as well as both
oestrogens and corticosteroids (during which GnRH analogue
therapy was stopped). A phase II chemotherapy study was
undertaken. Patients who were not biochemically castrate on
steroids and oestrogens and had a rising PSA had GnRH therapy
reinstituted and only when this failed to control their PSA were
they eligible for chemotherapy. To increase patient acceptance two
orally active chemotherapy agents, chlorambucil and lomustine,
were selected. These were active drugs when tested in the early
1980s by less stringent criteria than used today and had response
rates of 30–46% (Catane et al, 1978; Loening et al, 1981; Herr,
1982; Ruff et al, 1989). Although these earlier results are of use in
suggesting some activity, the absolute percentages cannot be
compared to the more recent data from the post-PSA era. As the
combination had shown good activity with low toxicity in
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srefractory lymphoma (Oza et al, 1993), we set out to study this
combination in absolute hormone refractory prostate cancer. This
paper reports these preliminary findings.
PATIENTS AND METHODS
Patients were eligible for the study if they had histologically
documented adenocarcinoma of the prostate with progression
despite androgen deprivation followed by second-line hormonal
therapy with steroids and oestrogens and were chemotherapy
naı ¨ve.
On becoming androgen independent (as judged by rising PSA in
the presence of castrate levels of testosterone (o1.5nmoll
 1))
patients were treated with diethylstilbestrol 1mgday
 1 combined
with a steroid (either dexamethasone 2mgday
 1 or hydrocorti-
sone 20mg twice a day or prednisolone 20mgday
 1) without a
GnRH analogue. Following documented biochemical or sympto-
matic progression, the serum testosterone was rechecked and if
they were still biochemically castrate they were eligible for
chemotherapy. If not, androgen deprivation was recommenced
and only if there were no response to this would chemotherapy be
offered. Patients had their GnRH therapy stopped at the start of
chemotherapy.
Assessable disease consisted of soft tissue disease or a rising
PSA. Patients were required to have an Eastern Cooperative
Oncology Group status of 0–3. Required haematological para-
meters were platelets greater than 100 10
9l
 1, granulocytes
greater than 3 10
9l
 1 and haemoglobin greater than 90gl
 1
(transfusions were permitted). The study was approved by Local
Research Ethics Committee (LREC) and all patients gave written
informed consent prior to participation.
Treatment and evaluation
Treatment consisted of chlorambucil at 1mgkg
 1 (given at 6mg a
day until the total dose reached) and lomustine at 2mgkg
 1 on
day 1. The dose of lomustine was reduced to 1mgkg
 1 if
radiotherapy to more than three sites had previously been given.
Granisetron 1mg orally day 1, dexamethasone 8mg day 1 and
4mgday
 1 on days 2 and 3 as well as metoclopramide 20mg 3 /
day for 3 days were prescribed as antiemetics. This cycle was
repeated every 56 days (CL56). Patients were asked to complete
quality of life forms both general and prostate specific. (EORTC –
QLQ 30 with PR 25 prior to treatment and on day 1 on subsequent
cycles). Once started on chemotherapy all hormone therapy was
stopped, including if possible, a phased reduction of steroids. If
pain worsened or the patient developed steroid deficiency
symptoms, they remained on their original dose of steroids until
it was clear whether they were responding when a further phased
reduction was attempted.
Patients were evaluated for response at the end of cycle 1. If the
disease was responding or stable, further cycles were given to a
maximum of six cycles. Progression (PD) on PSA was defined as an
increase of greater than 25% over nadir that was then confirmed
with a second rising PSA. Those patients with soft tissue disease
were assessed on CT scan. Repeat blood tests were carried out on
days 1, 22 and 36 of each cycle, including a full blood count, urea
and electrolytes, alkaline phosphatase and PSA.
The date of progression was defined as that of the first CT that
showed new lesions or a 25% increase in previously measured
disease, or showing a rise in PSA. PSA responses were evaluated
using the guidelines from the prostate-specific antigen working
group for PSA response in androgen independent disease (Bubley
et al, 1999). In the first cycle if the PSA was rising but there were
clinical signs of improvement then a second cycle was given. If it
became clear that the PSA continued to rise in the second cycle
then the date of progression was taken on the first confirmed rise
in PSA. In some patients, this was 21 days into the first cycle. For
those whose PSA rose in the first 8 weeks and then fell, the date of
progression was the first confirmed rise in the second or
subsequent cycle. A 50% fall in PSA maintained for 4 weeks was
termed a partial response (PR). Patients whose PSA stabilised for
more than 8 weeks, that is, did not rise by 25% or fall by greater
than 50% were considered as stable disease. Normalisation of PSA
(less than 4ngml
 1) confirmed for 1 month was termed a
complete response (CR).
Dose modifications
Prior to each chemotherapy cycle, platelets greater than
80 10
9l
 1 and white cell count greater than 3.0 10
9l
 1 were
needed. Patients with low counts were delayed for a week or until
the blood count recovered. Failure to recover counts in 4 weeks
meant the patient went off study.
If a delay was required, the doses of lomustine and chlorambucil
were reduced by 25%. If the nadir platelet count was o20 10
9l
 1,
the dose of lomustine was reduced by 50% on subsequent cycles. If
nadir platelet count was between 21 and 49 10
9l
 1, the
subsequent lomustine dose was reduced by 25%.
Patients who had received prior treatment with strontium or
previous radiotherapy to three or more sites received a reduced
dose of lomustine of 1mgkg
 1. If the nadir platelet count was
greater than 50 10
9, the lomustine dose was increased to
2mgkg
 1 on subsequent cycles.
Statistical design and analyses
The log-rank test was used to look at which variables were
significant on univariate analysis for overall survival and progres-
sion-free survival. The Wilcoxon matched pairs signed rank sum
test was used to look at changes in Quality of Life scores from
baseline to 8 weeks. Fishers exact test was used when the numbers
expected were less than 5.
RESULTS
Patient characteristics (Table 1)
Between the 3 November 2000 and the 20 September 2002, 37
patients were recruited into this study, their median performance
status was 1 (range 0–3). A total of 89% were symptomatic and
19% had extensive visceral disease (liver or lung metastases). Only
48% had normalised their PSA with androgen deprivation despite
the fact that 49% had received initial MAB. The median time to
androgen independence for the group was 23.5 months and the
median time between androgen independence and receiving
chemotherapy was 14 months.
Toxicity (see Table 2)
A median of two cycles of therapy was administered. No grade 4
toxicity was seen. The most significant problems were malaise
(grade 3 in 14%), and constipation (grade 3 in 12%), which reflects
in part the high frequency of opioid analgesia in this group of
advanced end stage patients. Haematological toxicity was mild
with only 4% having grade 3 leukopenia and 11% grade 3
thrombocytopenia.
Treatment outcomes
The overall results are summarised in Table 3. Biochemical
response rate to CL56 was 10% (one normalisation of PSA and two
with a greater than 50% response). An additional 46% achieved
stabilisation of their disease beyond 8 weeks and overall 54% had a
symptomatic response. The median time to progression was 3.6
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smonths (95% CI 2.3–4.9) (CR/PR 4.4 months, SD 3.7 months, PD
0.9 months) with an overall survival of 7.1 months (CR/PR 8.8
months, SD 10.9 months, PD 4.8 months). The median survival
from becoming androgen independent was 23.5 months (95% CI
17.0–29.8).
Eight out of 17 patients with SD had an initial rise in PSA in the
first 3–8 weeks (median rise 99% range 8–794%) followed by
plateau and then a fall 2 weeks later (median fall 29% from the
peak, range 7–63%). In three of eight, these declines lasted more
than 24 weeks though in two of the three, the minimum was still
higher than the pretreatment level.
Those who had SD at 8 weeks had a different subsequent
pattern of symptom response and PSA change than those who
progressed.
The PSA levels (median 198ngml
 1 for SD and 206ngml
 1 for
PD) and PSA doubling time prior to the start of chemotherapy
(median 80 days for SD and 78 days for PD/NE) were very similar
for the SD group and the PD/NE group. Those who had objective
biochemical responses had lower PSA levels (median 80ngml
 1)
and doubling time (median 46 days) at the start of chemotherapy
but numbers were small. However after treatment, there was a
marked difference in post-treatment PSA doubling time between
the SD and PD groups (217 vs 29 days).
Following progression on CL56, endocrine treatment was
restarted in 17 patients (Table 4). Two orchidectomised patients
failed to respond to addition of antiandrogens, though the only
Table 1 Pretreatment patient characteristics
Patient characteristics
Number of patients 37
Median age (range) 71.4 years (57.6–83.9)
Disease extent
Localised 1
Bone mets only 13
Bone+nodal disease 16
Bone+liver/lung 7
Performance score
02
11 8
21 1
35
Missing 1
Symptomatic
No 3
Yes 33
Missing 1
Primary therapy
GnRH 18
MAB 13
Orchidectomy 3
Antiandrogen monotherapy 3
PSA levels at start CL56
Median and (range) 183.5 (11.3–1560)
Alkaline phosphatase at start of CL56
p120 18
4120 19
Gleason score
8–10 6
5–7 17
p43
Missing 11
PSA normalised with prior androgen deprivation
No 16
Yes 15
Missing 6
Median time to androgen independence (AI) 25 months (range 4.4–136.7)
Number AIo2 years 17
Number AI42 years 20
Median time AI to start study 14.3 months (range 1.8–46.2)
Number AI to start studyo1 year 17
Number AI to start study 41 year 20
Table 2 WHO toxicity grade per cycle (in percentages)
Grade 1–2 (%) Grade 3 (%) Grade 4 (%)
Infection 4 0 0
Malaise 29 14 0
Taste 4 0 0
Nausea 14 2 0
Vomiting 2 0 0
Constipation 14 12 0
Diarrhoea 0 0 0
Stomatitis 0 0 0
Anorexia 17 8 0
Alopecia 0 0 0
Dyspnoea 10 0 0
Neuropathy 0 0 0
Hb 15 4 0
Wbc 20 4 0
Platelets 13 11 0
Table 3 Response and survival following CL56 and subsequent response
to further hormone therapy
Median no. of cycles: 2 (range 1–6)
Response to CL56
CR 1
PR 2
SD 17
PD 12
NE 5
Response rate
3/32 (10%)
Stabilisation rate (SD or better)
20/32 (63%)
Symptomatic improvement (24 evaluable)
No 13
Yes 11
Alk Phos response by week 8 (14 evaluable)
No 11
Yes 3
Median survival 7.1 months (95% CI 6.2–8.0)
Median time to progression 3.6 months (95% CI 2.3–4.9)
PF at 6 months 5/37
Median survival following AI 23.5 months (95% CI 17.2–29.8)
Post-CL56 hormones
Yes 17
Response to post-CL56 hormone therapy
Yes 9
450% 3
Chlorambucil and lomustine (CL56)
J Shamash et al
38
British Journal of Cancer (2005) 92(1), 36–40 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sone of these to be retreated with stilbestrol and dexamethasone
after failed antiandrogens responded a second time. In total, 13
patients received GnRH analogue for a second time. There were six
PSA falls, two of which were greater than 50%. Six of the 13
patients subsequently received diethylstilbestrol and dexametha-
sone after further progression on GnRH and two responded. There
was in addition one who received diethylstilbestrol and dexa-
methasone immediately after progression on CL56, and responded
with a fall in PSA of 45%. The median time from CL56 to starting
hormone therapy was greater in those who subsequently
responded to hormones again although this did not reach
statistical significance (8.0 vs 3.8 months, P¼0.085).
Hormone profiles (LH, FSH and testosterone) were repeated in
nine patients before secondary endocrine treatment was restarted.
Two were found not to be castrate and both responded to
subsequent treatment (15 and 55% falls in PSA falls, respectively).
Seven were castrate and two responded.
A total of 17 patients, who completed at least two courses of
treatment, returned quality of life questionnaires. Eight patients
showed some improvement (median improvement þ1.5 (quality
of life raw score)). In four patients there was no change. In five,
quality of life declined (median decline 2.0). There was no clear
relationship between Quality of Life changes and tumour response.
Prognostic factors
In terms of overall survival and time to progression, the following
were analysed: Gleason score, normalisation of PSA with prior
androgen deprivation, raised alkaline phosphatase, performance
status, PSA level, time to androgen independence, age, previous
steroid use (dexamethasone vs alternative steroid), period of time
of androgen independence prior to chemotherapy.
Of these, on univariate analyses only raised alkaline phosphatase
(5.5 months vs 8.8, P¼0.048), PSA above median (4185ngml
 1)
(5.5 vs 8.8 months P¼0.024) and time to androgen independence
of o1 year prior to chemotherapy (5.5 vs 46.4 months P¼0.03)
were significant for overall survival. For progression-free survival,
only prior dexamethasone vs another steroid (4.3 vs 2 months
P¼0.013) and time to androgen independence of 42 years (4.2 vs
2.4 months P¼0.049) were significant.
DISCUSSION
The objective response rate to the combination of chlorambucil
and lomustine (CL56) was modest (10%) and at first sight not very
encouraging.
The study was undertaken with these two drugs because the
response rate when the two drugs were used together in
chemorefractory lymphoma was higher than when used as single
agents (Oza et al, 1993).
There was a suggestion that patients with a lower PSA might be
more likely to respond as all responses occurred in patients with
PSA o110ngml
 1 (three out of 14 responses, PSA X110ngml
 1
zero out of 18 responses (P¼0.04 two-tailed Fisher’s exact test).
Patients who had stable disease at 8 weeks had a change in their
PSA velocity with a substantial reduction in doubling time during
chemotherapy. With the use of PSA velocity as a surrogate marker
being increasingly accepted, such findings may assume greater
significance (Carter et al, 2003; D’Amico et al, 2003; Rini et al,
2003). The lower response rate in this study particularly in
comparison to newer data from taxanes based studies (Eisenberger
et al, 2004; Petrylak et al, 2004) may in part be explained by the
fact that the patients in this study were resistant to corticosteroids
and oestrogens as well as to androgen deprivation.
The action of steroids in androgen independent prostate cancer
prior to chemotherapy appears more complicated than first
thought. The rationale for their use and dosing in this setting
was to suppress adrenal production of androgens. It appears that
other mechanisms may be important as different steroids have
different PSA response rates. In the recent preliminary analysis of
a randomised trial comparing dexamethasone alone to dexametha-
sone and diethylstilbestrol (Shamash et al, 2004), 51% had a PSA
response to dexamethasone. This is higher than the PSA response
to hydrocortisone – 21% (Dawson et al, 1995; Kantoff et al, 1999),
or prednisone – 17% (Dowling et al, 2001; Berry et al, 2002). One
explanation for this may be that receptors other than the androgen
receptor may be more important than previously appreciated in
determining prostate cancer responses. This raises the question as
to whether the hormonal responses postchemotherapy represent
separate clones being suppressed or whether the chemotherapy is
modulating the plasticity of the receptor profile on the tumour cell.
Table 4 Post-CL56 hormone characteristics and subsequent response in 17 patients
Post-CL56 treatment
Patient
no. Castrate
GnRH
analogue MAB
% PSA
decline
a
Duration
(months) Stilb/steroid
% PSA
decline
a
Duration
(months)
Time from CL56 to
postchemotherapy hormone
treatment (months)
1 Yes Yes Yes PD No — — 3.6
2
b Yes No Yes PD Yes 90% 11 19.0
3 Yes Yes Yes PD No — — 3.2
4 Yes Yes No 10% 2.5 Yes 20% 4 8.0
5 Yes Yes No PD — Yes PD — 5.5
6 Unknown No No — — Yes 45% 4 4.6
7 Unknown Yes Yes PD — Yes PD — 4.0
8
b Yes No Yes PD — — — — 8.2
9 No Yes No 55% 6 Yes PD — 9.1
10 Unknown Yes Yes 97% 6.0+ No — — 16.1
11 Unknown Yes No 45% 2 No — — 3.8
12 Yes Yes No 7% 3 No — — 7.2
13 Yes Yes No PD — — — — 2.5
14 Yes Yes No PD — — — — 3.8
15 Unknown Yes Yes 30% 3 Yes PD —
16 Yes No Yes PD — — — — 3.7
17 No Yes No PD — Yes 15% 2 3.8
MAB¼maximum androgen blockade. Stilb/steroid¼diethylstilbestrol and steroid.
aFrom the start of hormone therapy.
bPatient had orchidectomy.
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would have removed any androgen sensitive clones that had
survived GnRH monotherapy and it is these clones that were
responsible for the re-response to GnRH therapy following the
cessation of chemotherapy in this study.
A criticism of this study is that patients were not androgen
suppressed during chemotherapy. It could be that although
most remained biochemically castrate that androgen level could
have been kept lower by maintaining androgen deprivation
and even a small rise within the castrate range was responsible
for the growth of androgen dependent clone, which then
responded to the reinduction of androgen deprivation following
the failure of chemotherapy. We do not believe this to be the
dominant explanation. There are anecdotal reports of similar
secondary responses being seen in breast cancer patients
progressing on chemotherapy (Ragaz, 2001), and they provide
additional arguments for the use of sequential hormonal
and then chemotherapy rather than the use of both modalities
consecutively.
In conclusion, this study has demonstrated that use of a simple
oral chemotherapy regimen repeated every 8 weeks sequentially
following the failure of oestrogens and steroids in the management
of androgen independent prostate cancer produces evidence of
antitumour activity in nearly 2/3rds of such end stage patients
based on slowing of tumour doubling time despite a low PSA
response rate. It is well tolerated and the survival in this cohort
compares favourably with that seen in the current more toxic
taxane/estramustine based combinations. There is an urgent need
to prospectively analyse secondary hormone responses following
chemotherapy so that their frequency and duration may be more
accurately determined.
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